Literature DB >> 24155642

Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.

T Di Valentin1, J Biagi, S Bourque, R Butt, P Champion, V Chaput, B Colwell, C Cripps, M Dorreen, S Edwards, C Falkson, D Frechette, S Gill, R Goel, D Grant, N Hammad, A Jeyakumar, M L'espérance, C Marginean, J Maroun, M Nantais, N Perrin, C Quinton, M Rother, B Samson, J Siddiqui, S Singh, S Snow, E St-Hilaire, M Tehfe, M Thirlwell, S Welch, L Williams, F Wright, R Goodwin.   

Abstract

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Halifax, Nova Scotia, October 20-22, 2011. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management of rectal cancer, including pathology reporting, neoadjuvant systemic and radiation therapy, surgical techniques, and palliative care of rectal cancer patients. Other topics discussed include multidisciplinary cancer conferences, treatment of gastrointestinal stromal tumours and pancreatic neuroendocrine tumours, the use of folfirinox in pancreatic cancer, and treatment of stage ii colon cancer.

Entities:  

Keywords:  Consensus guideline; folfirinox; gastrointestinal stromal tumours; mccs; palliative care; pancreatic neuroendocrine tumours; rectal cancer

Year:  2013        PMID: 24155642      PMCID: PMC3805414          DOI: 10.3747/co.20.1638

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  48 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Authors:  Monica M Bertagnolli; Mark Redston; Carolyn C Compton; Donna Niedzwiecki; Robert J Mayer; Richard M Goldberg; Thomas A Colacchio; Leonard B Saltz; Robert S Warren
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

3.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

4.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 5.  The role of methadone in cancer pain treatment--a review.

Authors:  W Leppert
Journal:  Int J Clin Pract       Date:  2009-07       Impact factor: 2.503

Review 6.  Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.

Authors:  Shreyaskumar Patel; John R Zalcberg
Journal:  Eur J Cancer       Date:  2008-01-29       Impact factor: 9.162

7.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 9.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

10.  The role of collegial interaction in continuing professional development.

Authors:  Anna R Gagliardi; Frances C Wright; Michael A B Anderson; Dave Davis
Journal:  J Contin Educ Health Prof       Date:  2007       Impact factor: 1.355

View more
  3 in total

Review 1.  Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

Authors:  Aurélien Lambert; Céline Gavoille; Thierry Conroy
Journal:  Therap Adv Gastroenterol       Date:  2017-06-27       Impact factor: 4.409

2.  Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

Authors:  Carmel Jacobs; Ian D Graham; Julie Makarski; Michaël Chassé; Dean Fergusson; Brian Hutton; Mark Clemons
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

3.  Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.

Authors:  Braden Woodhouse; Sharon Pattison; Eva Segelov; Simron Singh; Kate Parker; Grace Kong; William Macdonald; David Wyld; Goswin Meyer-Rochow; Nick Pavlakis; Siobhan Conroy; Vallerie Gordon; Jonathan Koea; Nicole Kramer; Michael Michael; Kate Wakelin; Tehmina Asif; Dorothy Lo; Timothy Price; Ben Lawrence
Journal:  J Clin Med       Date:  2019-09-12       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.